

**Mancusi-Ungaro, Michael - OCI**

---

**From:** Gingerich, Lisa M (12710) <lmgingerich@michaelbest.com>  
**Sent:** Monday, February 18, 2019 5:26 PM  
**To:** Mancusi-Ungaro, Michael - OCI  
**Cc:** 'Cari Logemann'; 'Brett Davis'; Madani, Syed T (12736)  
**Subject:** Aspirus Filing - Case No. 19-C42970 (letter in response to 2/8/19 correspondence  
**Attachments:** 2019.02.18 Response to OCI - Confidential.pdf; 2019.02.18 - Response to OCI - Public.pdf

Dear Mr. Mancusi-Ungaro:

Attached are Aspirus, Inc.'s letter (with exhibits) in response to your letter dated February 8, 2019 in regard to Case No. 19-C42970. We have included one confidential version and one public version of the letter and its exhibits. In the public version of the letter, we respectfully request the confidentiality of certain information regarding the Stock Transfer Agreement and the financial projections/business plan for Aspirus Arise Health Plan of Wisconsin. The support for the requested confidential treatment was set forth in our January 14, 2019 letter. Please let us know if you need anything else from us in regard to this matter and thank you for consideration.

Lisa M. Gingerich  
Partner  
Leader, Healthcare  
T: 414.270.2710 | michaelbest.com  
Michael Best & Friedrich LLP

Exh #	B 20
Date	
Case	19-C42970
Ins. Comm.	

Email Disclaimer

\*\*\*\*\*

The information contained in this communication may be confidential, is intended only for the use of the recipient(s) named above, and may be legally privileged. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this communication in error, please return it to the sender immediately and delete the original message and any copy of it from your computer system. If you have any questions concerning this message, please contact the sender.

=====